Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-pftt2 Total loading time: 0 Render date: 2024-06-02T21:02:57.627Z Has data issue: false hasContentIssue false

Chapter 21 - Mastocytosis and Myeloid Lymphoid Neoplasms with Eosinophilia

from Section IV - Precursor Hematopoietic Neoplasms and Related Neoplasms

Published online by Cambridge University Press:  25 November 2023

By
Karen M. Chisholm  and
Tracy I. George
Edited by
Silvia Tse Bunting ,
Xiayuan Liang ,
Michele E. Paessler  and
Satheesh Chonat
Silvia Tse Bunting
Affiliation:
Cleveland Clinic Florida Weston
Xiayuan Liang
Affiliation:
University of Colorado
Michele E. Paessler
Affiliation:
University of Pennsylvania School of Medicine
Satheesh Chonat
Affiliation:
Emory University, Atlanta
Get access

Summary

Mastocytosis is defined as a clonal proliferation of neoplastic mast cells in one or more organ systems. It is broadly separated into two categories of cutaneous mastocytosis and systemic mastocytosis, of which the latter can include cutaneous involvement. In the 2016 World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues, mastocytosis was separated into its own category due to its heterogeneous clinical manifestations ranging from spontaneously resolving skin lesions in pediatric cutaneous mastocytosis to highly aggressive malignancies such as mast cell leukemia with short survival and multiorgan involvement [1, 2].

Type
Chapter
Information
Atlas of Pediatric Hematopathology , pp. 247 - 256
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Arber, DA, Orazi, A, Hasserjian, RP, Brunning, RD, Le Beau, MM, Porwit, A, et al. Introduction and overview of the classification of myeloid neoplasms. In Swerdlow, SH, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017:16–27.Google Scholar
Vardiman, JW, Brunning, RD, Arber, DA, Le Beau, MM, Porwit, A, Tefferi, A, et al. Introduction and overview of the classification of the myeloid neoplasms. In Swerdlow, SH, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008:18–30.Google Scholar
Hartmann, K, Escribano, L, Grattan, C, Brockow, K, Carter, MC, Alvarez-Twose, I, et al. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016; 137(1): 35–45.CrossRefGoogle ScholarPubMed
Carter, MC, Bai, Y, Ruiz-Esteves, KN, Scott, LM, Cantave, D, Bolan, H, et al. Detection of KIT D816V in peripheral blood of children with manifestations of cutaneous mastocytosis suggests systemic disease. Br J Haematol. 2018; 183(5): 775–82.CrossRefGoogle ScholarPubMed
Carter, MC, Clayton, ST, Komarow, HD, Brittain, EH, Scott, LM, Cantave, D, et al. Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis. J Allergy Clin Immunol. 2015; 136(6): 1673–9 e3.CrossRefGoogle ScholarPubMed
Horny, H-P, Akin, C, Arber, DA, Peterson, LC, Tefferi, A, Metcalfe, DD, et al. Mastocytosis. In Swerdlow, SH, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017:62–9.Google Scholar
Gadage, VS, Kadam Amare, PS, Galani, KS, Mittal, N. Systemic mastocytosis with associated acute myeloid leukemia with t (8; 21) (q22; q22). Indian J Pathol Microbiol. 2012; 55(3): 409–12.CrossRefGoogle Scholar
Johnson, RC, Savage, NM, Chiang, T, Gotlib, JR, Cherry, AM, Arber, DA, et al. Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22). Am J Clin Pathol. 2013; 140(4): 525–35.CrossRefGoogle Scholar
Rabade, N, Tembhare, P, Patkar, N, Amare, P, Arora, B, Subramanian, PG, et al. Childhood systemic mastocytosis associated with t (8; 21) (q22; q22) acute myeloid leukemia. Indian J Pathol Microbiol. 2016; 59(3): 407–9.Google Scholar
Mahadeo, KM, Wolgast, L, McMahon, C, Cole, PD. Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia. Pediatr Blood Cancer. 2011; 57(4): 684–7.CrossRefGoogle Scholar
Bain, BJ, Horny, H-P, Hasserjian, RP, Orazi, A. Chronic eosinophilic leukaemia, NOS. In Swerdlow, SH, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017:54–6.Google Scholar
Patterer, V, Schnittger, S, Kern, W, Haferlach, T, Haferlach, C. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1. Ann Hematol. 2013; 92(6): 759–69.CrossRefGoogle ScholarPubMed
Bain, BJ, Horny, H-P, Arber, DA, Tefferi, A, Hasserjian, RP. Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2. In Swerdlow, SH, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017:72–9.Google Scholar
Farruggia, P, Giugliano, E, Russo, D, Trizzino, A, Lorenzatti, R, Santoro, A, et al. FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome in childhood: A case report and review of literature. J Pediatr Hematol Oncol. 2014; 36(1): e28–e30.CrossRefGoogle ScholarPubMed
Rathe, M, Kristensen, TK, Moller, MB, Carlsen, NL. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate. Pediatr Blood Cancer. 2010; 55(4): 730–2.CrossRefGoogle ScholarPubMed
Rives, S, Alcorta, I, Toll, T, Tuset, E, Estella, J, Cross, NC. Idiopathic hypereosinophilic syndrome in children: Report of a 7-year-old boy with FIP1L1-PDGFRA rearrangement. J Pediatr Hematol Oncol. 2005; 27(12): 663–5.CrossRefGoogle ScholarPubMed
Oberley, MJ, Denton, C, Ji, J, Hiemenz, M, Bhojwani, D, Ostrow, D, et al. A neoplasm with FIP1L1-PDGFRA fusion presenting as pediatric T-cell lymphoblastic leukemia/lymphoma without eosinophilia. Cancer Genet. 2017; 216–17: 91–9.Google ScholarPubMed
Reiter, A, Gotlib, J. Myeloid neoplasms with eosinophilia. Blood. 2017; 129(6): 704–14.CrossRefGoogle ScholarPubMed
Abraham, S, Salama, M, Hancock, J, Jacobsen, J, Fluchel, M. Congenital and childhood myeloproliferative disorders with eosinophilia responsive to imatinib. Pediatr Blood Cancer. 2012; 59(5): 928–9.CrossRefGoogle ScholarPubMed
Bielorai, B, Leitner, M, Goldstein, G, Mehrian-Shai, R, Trakhtenbrot, L, Fisher, T, et al. Sustained response to imatinib in a pediatric patient with concurrent myeloproliferative disease and lymphoblastic lymphoma associated with a CCDC88C-PDGFRB fusion gene. Acta Haematol. 2019; 141(2): 119–27.CrossRefGoogle Scholar
Hidalgo-Curtis, C, Apperley, JF, Stark, A, Jeng, M, Gotlib, J, Chase, A, et al. Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms. Br J Haematol. 2010; 148(2): 268–73.CrossRefGoogle Scholar
Brown, LM, Bartolo, RC, Davidson, NM, Schmidt, B, Brooks, I, Challis, J, et al. Targeted therapy and disease monitoring in CNTRL-FGFR1-driven leukaemia. Pediatr Blood Cancer. 2019; 66(10): e27897.CrossRefGoogle ScholarPubMed
Chen, X, Zhang, Y, Li, Y, Lei, P, Zhai, Y, Liu, L. Biphenotypic hematologic malignancy: A case report of the 8p11 myeloproliferative syndrome in a child. J Pediatr Hematol Oncol. 2010; 32(6): 501–3.CrossRefGoogle ScholarPubMed
Dolan, M, Cioc, A, Cross, NC, Neglia, JP, Tolar, J. Favorable outcome of allogeneic hematopoietic cell transplantation for 8p11 myeloproliferative syndrome associated with BCR-FGFR1 gene fusion. Pediatr Blood Cancer. 2012; 59(1): 194–6.CrossRefGoogle ScholarPubMed
Lv, H, Hu, S, Lu, J, Zhai, Q, Zhai, Z, Du, Z, et al. Precursor T-lymphoblastic lymphoma associated with t(8;9)(p11.2;q33): A case report and review of the literature. Acta Haematol. 2018; 139(3): 176–82.CrossRefGoogle Scholar
Wong, WS, Cheng, KC, Lau, KM, Chan, NP, Shing, MM, Cheng, SH, et al. Clonal evolution of 8p11 stem cell syndrome in a 14-year-old Chinese boy: A review of literature of t(8;13) associated myeloproliferative diseases. Leuk Res. 2007; 31(2): 235–8.CrossRefGoogle Scholar
Macdonald, D, Reiter, A, Cross, NC. The 8p11 myeloproliferative syndrome: A distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. 2002; 107(2): 101–7.CrossRefGoogle ScholarPubMed
Murati, A, Gelsi-Boyer, V, Adelaide, J, Perot, C, Talmant, P, Giraudier, S, et al. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia. 2005; 19(9): 1692–6.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×